A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis
- Registration Number
- NCT00399906
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The purpose of this clinical research study is to learn if BMS-582949 alone is an effective treatment for moderate to severe psoriasis. The safety of the drug and the effectiveness of each dose will also be studied.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 99
Inclusion Criteria
- Males and Females (not nursing or not pregnant)
- 18-75 years of age
- Diagnosis of moderate to severe psoriasis for at least six months at the time of screening
- Subjects will require wash-out of certain therapies for the treatment of psoriasis but will be allowed to continue on certain topical therapies
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description A2 BMS-582949 30 mg P1 Placebo 10 or 100 mg A1 BMS-582949 10 mg A3 BMS-582949 100 mg
- Primary Outcome Measures
Name Time Method The primary endpoint is the proportion of subjects achieving an IGA score of clear or almost clear at Week 12 at Week 12
- Secondary Outcome Measures
Name Time Method Proportion of subjects achieving a PASI-50 at Week 12 Proportion of subjects achieving a PASI-90 at Week 12 Proportion of subjects achieving a PASI-75 at Week 12
Trial Locations
- Locations (1)
Local Institution
🇲🇽Monterrey, Nuevo Leon, Mexico